ࡱ;   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry  \pCalc Ba=`  !"#$%&'()*+,-./0=@ 8X@"1Calibri1Arial1Arial1Arial1Calibri1Calibri General;6_(\$* #,##0.00_);_(\$* \(#,##0.00\);_(\$* \-??_);_(@_) #,##0 #,##0.003._(\$* #,##0_);_(\$* \(#,##0\);_(\$* \-_);_(@_)\(#,##0_);[RED]\(#,##0\)!"($"#,##0_);[RED]"($"#,##0\)'""($"#,##0.00_);[RED]"($"#,##0.00\)#\(#,##0.00_);[RED]\(#,##0.00\)                + ) , *   (  (  $ (8 (      $      $  $   ( ( `ppart iiH part ii-1 part ii-2"treasury share repurchases"Dcomparison of cumulative t$^comparison of cumulative t-1"tabular disclosure of cont$ltabular disclosure of cont-1$tabular disclosure of cont-2$tabular disclosure of cont-3$tabular disclosure of cont-4balance sheetsv advaxis inc"statements of shareholders  advaxis inc-1"supplemental disclosures o"0supplemental schedule of nnet loss per share 3 investments!3 investments-1 &4 property and equipment+5 intangible assets05 intangible assets-1D36 accrued expenses"z78 common stock purchase wal>warrant liability"B9 share based compensation#(Hrestricted stock units rsushN stock optionsUstock options-1_stock options-2$cshares issued to consultants *hoffice laboratory leasel12 income taxes8q12 income taxes-1v12 income taxes-2{12 income taxes-3"L16 selected quarterly fina$16 selected quarterly fina-1$N16 selected quarterly fina-2 advaxis inc-2 exhibit 231"Vsection 302 of the sarbane$section 302 of the sarbane-1$Ğsection 302 of the sarbane-2$section 302 of the sarbane-3".as adopted pursuant to sec$Ҩas adopted pursuant to sec-1T100      !"#$%&'()*+,-./03  @@   .PART II Fiscal 2016HighLowFourth Quarter Third QuarterSecond Quarter First Quarter Fiscal 2015 Fiscal 2014Treasury Share RepurchasesPeriod+(a) Total Number of Shares Purchased (1)#(b) Average Price Paid Per Share[(c) Total Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsR(d) Maximum Dollar Value of Shares that May Yet Be Purchased Under the Program$November 1, 2015  November 30, 2015N/A$December 1, 2015  December 31, 2015"January 1, 2016  January 31, 2016$February 1, 2016  February 29, 2016March 1, 2016  March 31, 2016April 1, 2016  April 30, 2016May 1, 2016  May 31, 2016June 1, 2016  June 30, 2016July 1, 2016  July 31, 2016 August 1, 2016  August 31, 2016&September 1, 2016  September 30, 2016"October 1, 2016  October 31, 2016Total&COMPARISON OF CUMULATIVE TOTAL RETURN*Year Ended October 31,20162015201420132012Statements of Operations Data:Revenue$-Operating Expenses:!Research and Development Expenses#General and Administrative ExpensesTotal Operating ExpensesLoss from OperationsOther Income (Expense):Interest Income3Net Changes in Fair Value of Derivative Liabilities(Loss) on Note Retirement-Other Income (Expense), Net"Net Loss Before Income Tax BenefitIncome Tax Benefit*Dividends Attributable to Preferred Shares#Net Loss Applicable to Common StockNet Loss,Net Loss per Common Share, Basic and DilutedGWeighted Average Number of Common Shares Outstanding, Basic and Diluted October 31,Balance Sheet Data:<Cash and Cash Equivalents and Investments  Held-to-MaturityWorking Capital Total AssetsCommon Stock Warrant LiabilityAccumulated DeficitTotal Shareholders Equity-Tabular Disclosure of Contractual ObligationsPayments Due by PeriodContractual ObligationsLess than 1 year 1-3 years 3-5 yearsMore than 5 yearsOperating Leases/Employment Agreements Subject to Annual RenewalConsulting and other ServicesExhibit NumberDescription of ExhibitsForm of Common Stock Purchase Warrant. Incorporated by reference to Exhibit 4.2 to Current Report on Form 8-K filed with the SEC on January 5, 2012.0Form of Common Stock Purchase Warrant issued pursuant to the Exchange Agreements, dated as of May 14, 2012, by and between Advaxis, Inc. and each investor identified on the signature pages thereto. Incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed with the SEC on May 18, 2012.4Form of Common Stock Purchase Warrant issued pursuant to the note purchase agreement, dated as of May 14, 2012, by and between Advaxis, Inc. and each investor identified on the signature pages thereto. Incorporated by reference to Exhibit 4.3 to Current Report on Form 8-K filed with the SEC on May 18, 2012.Form of Common Stock Purchase Warrant issued to Dr. James Patton. Incorporated by reference to Exhibit 4.23 to Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-183682) filed with the SEC on September 11, 2012.Form of Representative s Warrant. Incorporated by reference to Exhibit 4.19 to Registration Statement on Form S-1/A (File No. 333-188637) filed with the SEC on September 27, 2013.Form of Warrant to Purchase 30,154 Shares of Common Stock issued September 17, 2013 pursuant to an engagement letter termination agreement. Incorporated by reference to Exhibit 4.20 to Registration Statement on Form S-1/A (File No. 333-188637) filed with the SEC on September 27, 2013.Common Stock purchase warrant, dated as of March 19, 2014, by and between Advaxis, Inc. and Aratana Therapeutics, Inc. Incorporated by reference to Exhibit 4.1 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.Form of Representative s Warrant related to the Underwriting Agreement, dated as of March 31, 2014, by and between Advaxis, Inc. and Aegis Capital Group. Incorporated by reference to Exhibit 4.2 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.2004 Stock Option Plan of the registrant. Incorporated by reference to Exhibit 4.1 to Report on Form S-8 filed with the SEC on December 1, 2005.2005 Stock Option Plan of the registrant. Incorporated by reference to Annex A to DEF 14A Proxy Statement filed with the SEC on May 15, 2006.License Agreement, between the Trustees of the University of Pennsylvania and the registrant dated as of June 17, 2002, as Amended and Restated on February 13, 2007. Incorporated by reference to Exhibit 10.11 to Annual Report on Form 10-KSB filed with the SEC on February 13, 2007.Amended and Restated 2009 Stock Option Plan of the registrant. Incorporated by reference to Annex A to DEF 14A Proxy Statement filed with the SEC on April 30, 2010.Second Amendment to the Amended and Restated Patent License Agreement between the registrant and the Trustees of the University of Pennsylvania dated as of May 10, 2010. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on June 3, 2010.Note purchase agreement, dated as of May 9, 2011, by and between Advaxis, Inc. and each investor identified on the signature pages thereto. Incorporated by reference to Exhibit 10.1 to Amendment to Current Report on Form 8-K/A filed with the SEC on May 12, 2011.2011 Omnibus Incentive Plan of registrant. Incorporated by reference to Annex A to DEF 14A Proxy Statement filed with the SEC on August 29, 2011.2011 Employee Stock Purchase Plan. Incorporated by reference to Annex B to DEF 14A Proxy Statement filed with the SEC on August 29, 2011.Amendment No. 1 to the Advaxis, Inc. 2011 Employee Stock Purchase Plan. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on December 20, 2011.Exchange Agreement, dated as of May 14, 2012, by and between Advaxis, Inc. and each investor identified on the signature pages thereto. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on May 18, 2012.Amendment, Consent and Waiver Agreement, dated as of May 14, 2012, by and between Advaxis, Inc. and each investor identified on the signature pages thereto. Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on May 18, 2012.2Form of Convertible Promissory Note issued pursuant to the note purchase agreement, dated as of May 14, 2012, by and between Advaxis, Inc. and each investor identified on the signature pages thereto. Incorporated by reference to Exhibit 4.2 to Current Report on Form 8-K filed with the SEC on May 18, 2012.Note purchase agreement, dated as of May 14, 2012, by and between Advaxis, Inc. and each investor identified on the signature pages thereto. Incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the SEC on May 18, 2012.Registration Rights Agreement, dated as of May 14, 2012, by and between Advaxis, Inc. and each investor identified on the signature pages thereto. Incorporated by reference to Exhibit 10.4 to Current Report on Form 8-K filed with the SEC on May 18, 2012.HAmendment No. 1, dated as of March 26, 2007, to the License Agreement, between the Trustees of the University < of Pennsylvania and Advaxis, Inc. dated as of June 17, 2002, as amended and restated on February 13, 2007. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on June 14, 2012.KAmendment No. 3, dated as of December 12, 2011, to the License Agreement, between the Trustees of the University of Pennsylvania and Advaxis, Inc. dated as of June 17, 2002, as amended and restated on February 13, 2007. Incorporated by reference to Exhibit 10.5 to Quarterly Report on Form 10-Q filed with the SEC on June 14, 2012.Amendment No. 1 to 2011 Omnibus Incentive Plan of registrant. Incorporated by reference to Annex B to DEF 14A Proxy Statement filed with the SEC on July 19, 2012.10.18 ! Employment Agreement by and between Advaxis, Inc. and Daniel J. O Connor, dated August 19, 2013. Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on August 20, 2013.Indemnification Agreement. Incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the SEC on August 20, 2013.10.20 ! Employment Agreement between Advaxis, Inc. and Robert Petit, dated September 26, 2013. Incorporated by reference to Exhibit 10.70 to Registration Statement on Form S-1/A (File No. 333-188637) filed with the SEC on September 27, 2013.10.21! Employment Agreement by and between Advaxis, Inc. and Gregory T. Mayes, III, dated October 25, 2013. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on October 29, 2013.10.22! Restricted Stock Agreement between Advaxis, Inc. and Gregory T. Mayes, III, dated October 25, 2013. Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on October 29, 2013.Exclusive License and Technology Transfer Agreement by and between Advaxis, Inc. and Global BioPharma, Inc., dated December 9, 2013. Incorporated by reference to Exhibit 10.79 to Annual Report on Form 10-K/A filed with the SEC on February 6, 2014.10.24! Amendment No. 1, dated as of December 19, 2013, to the Employment Agreement by and between Advaxis, Inc. and Daniel J. O Connor. Incorporated by reference to Exhibit 10.82 to Annual Report on Form 10-K/A filed with the SEC on February 6, 2014.10.25! Amendment No. 1, dated as of December 19, 2013, to the Employment Agreement by and between Advaxis, Inc. and Gregory T. Mayes, III. Incorporated by reference to Exhibit 10.82 to Annual Report on Form 10-K/A filed with the SEC on February 6, 2014.10.26! Amendment No. 1, dated as of December 19, 2013, to the Employment Agreement by and between Advaxis, Inc. and Mark J. Rosenblum. Incorporated by reference to Exhibit 10.82 to Annual Report on Form 10-K/A filed with the SEC on February 6, 2014.10.27! Amendment No. 1, dated as of December 19, 2013, to the Employment Agreement by and between Advaxis, Inc. and Robert G. Petit. Incorporated by reference to Exhibit 10.82 to Annual Report on Form 10-K/A filed with the SEC on February 6, 2014.Distribution and Supply Agreement, dated as of January 20, 2014, by and between Advaxis, Inc. and Biocon, Limited. Incorporated by reference to Exhibit 10.7 to Quarterly Report on Form 10-Q filed with the SEC on March 17, 2014.Exclusive License Agreement, dated March 19, 2014, by and between Advaxis, Inc. and Aratana Therapeutics, Inc. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.10.30! Employment Agreement, dated March 24, 2014, by and between Advaxis, Inc. and Sara M. Bonstein. Incorporated by reference to Exhibit 10.2 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.10.31! Separation Agreement and General Release, dated March 24, 2014, between Advaxis, Inc. and Mark J. Rosenblum. Incorporated by reference to Exhibit 10.3 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.10.32! Amendment No. 2, dated as of June 5, 2014, to the Employment Agreement by and between Advaxis, Inc. and Daniel J. O Connor. Incorporated by reference to Exhibit 10.4 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.10.33! Amendment No. 2, dated as of June 5, 2014, to the Employment Agreement by and between Advaxis, Inc. and Gregory T. Mayes. Incorporated by reference to Exhibit 10.5 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.10.34! Amendment No. 2, dated as of June 5, 2014, to the Employment Agreement by and between Advaxis, Inc. and Robert G. Petit. Incorporated by reference to Exhibit 10.6 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.10.35! Amendment No. 1, dated as of June 5, 2014, to the Employment Agreement by and between Advaxis, Inc. and Sara M. Bonstein. Incorporated by reference to Exhibit 10.8 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.10.36! Employment Agreement, dated October 20, 2014, by and between Advaxis, Inc. and David J. Mauro. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on October 21, 201410.37! Form of Restricted Stock Agreement between Advaxis, Inc. and David J. Mauro, dated October 20, 2014. Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on October 21, 2014.Clinical Trial Collaboration Agreement, dated July 21, 2014, by and between Advaxis, Inc. and MedImmune, LLC. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on September 9, 2014.5th Amendment to the Amended & Restated License Agreement, dated July 25, 2014, by and between Advaxis, Inc. and University of Pennsylvania. Incorporated by reference to Exhibit 10.2 to Quarterly Report on Form 10-Q filed with the SEC on September 9, 2014.Amendment No. 2 to the Advaxis, Inc. 2011 Omnibus Incentive Plan, effective July 9, 2014. Incorporated by reference to Annex A to Current Report on Schedule 14A filed with the SEC on May 20, 2014.Amended and Restated 2011 Omnibus Incentive Plan, dated September 8, 2014. Incorporated by reference to Exhibit 10.4 to Quarterly Report on Form 10-Q filed with the SEC on September 9, 2014.Master Services Agreement for Technical Transfer and Clinical Supply, dated February 5, 2014, by and between Advaxis, Inc. and SynCo Bio Partners B.V. Incorporated by reference to Exhibit 10.1 to Current Report to Form 8-K filed with the SEC on February 11, 2014.Clinical Trial Collaboration and Supply Agreement by and between Advaxis, Inc. and Merck & Co. dated August 22, 2014. Incorporated by reference to Exhibit 10.101 to Annual Report on Form 10-K filed with the SEC on January 6, 201510.44! Amendment No. 1, dated as of April 17, 2015, to the Employment Agreement by and between Advaxis, Inc and David J. Mauro. Incorporated by reference to Exhibit 10.2 to Quarterly Report on Form 10-Q filed with the SEC on June 15, 2015.10.45! Amendment No. 2, dated as of April 17, 2015, to the Employment Agreement by and between Advaxis, Inc and Sara M. Bonstein. Incorporated by reference to Exhibit 10.3 to Quarterly Report on Form 10-Q filed with the SEC on June 15, 2015.10.46! Amendment No. 3, dated as of April 17, 2015, to the Employment Agreement by and between < Advaxis, Inc and Daniel J. O Connor. Incorporated by reference to Exhibit 10.4 to Quarterly Report on Form 10-Q filed with the SEC on June 15, 2015.10.47! Amendment No. 3, dated as of April 17, 2015, to the Employment Agreement by and between Advaxis, Inc and Gregory T. Mayes. Incorporated by reference to Exhibit 10.5 to Quarterly Report on Form 10-Q filed with the SEC on June 15, 2015.10.48! Amendment No. 3, dated as of April 17, 2015, to the Employment Agreement by and between Advaxis, Inc and Robert G. Petit. Incorporated by reference to Exhibit 10.6 to Quarterly Report on Form 10-Q filed with the SEC on June 15, 2015.Exclusive License Agreement, dated August 25, 2015, by and between Advaxis, Inc. and Knight Therapeutics, Inc. Incorporated by reference to Exhibit 10.57 to Annual Report on Form 10-K filed with the SEC on January 8, 2016.Securities Purchase Agreement, dated as of August 25, 2015, between Advaxis, Inc., Knight Therapeutics Inc., and Sectoral Asset Management. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on August 28, 2015.10.51 ! Amendment No. 4, dated as of December 31, 2015, to the Employment Agreement by and between Advaxis, Inc and Robert G. Petit. Incorporated by reference to Exhibit 10.58 to Annual Report on Form 10-K filed with the SEC on January 8, 2016.10.52 ! Amendment No. 3, dated as of December 31, 2015, to the Employment Agreement by and between Advaxis, Inc and Sara M. Bonstein. Incorporated by reference to Exhibit 10.59 to Annual Report on Form 10-K filed with the SEC on January 8, 2016.10.53 ! Amendment No. 4, dated as of December 31, 2015, to the Employment Agreement by and between Advaxis, Inc and Daniel J. O Connor. Incorporated by reference to Exhibit 10.60 to Annual Report on Form 10-K filed with the SEC on January 8, 2016.10.54 ! Amendment No. 4, dated as of December 31, 2015, to the Employment Agreement by and between Advaxis, Inc and Gregory T. Mayes. Incorporated by reference to Exhibit 10.61 to Annual Report on Form 10-K filed with the SEC on January 8, 2016.Co-Development and Commercialization Agreement between Advaxis, Inc. and Especificos Stendhal SA de CV dated February 3, 2016. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on February 26, 2016.Change of Control Plan dated February 24, 2016. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on February 26, 2016. 10.57 ***fLicense and Collaboration Agreement, dated August 2, 2016, by and between Advaxis, Inc. and Amgen Inc.Securities Purchase Agreement, dated as of August 1, 2016, between Advaxis, Inc. and Amgen, Inc. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on August 2, 2016.Placement Agency Agreement, dated as of August 16, 2016, between Advaxis, Inc. Jefferies LLC and Barclay s Capital Inc., as representatives. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on August 16, 2016.BALANCE SHEETSASSETSCurrent Assets:Cash and Cash EquivalentsInvestments  Held-to-MaturityInterest ReceivablePrepaid ExpensesIncome Tax ReceivableDeferred ExpensesOther Current AssetsTotal Current Assets8Property and Equipment (net of accumulated depreciation)3Intangible Assets (net of accumulated amortization) Other Assets TOTAL ASSETS$LIABILITIES AND SHAREHOLDERS EQUITYCurrent Liabilities:Accounts PayableAccrued ExpensesDeferred RevenueLease Incentive ObligationBShort-term Convertible Notes and Fair Value of Embedded DerivativeTotal Current Liabilities Deferred Rent2Lease Incentive Obligation- net of current portionTotal Liabilities'Commitments and Contingencies  Note 11Shareholders Equity:Preferred Stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at October 31, 2016 and 2015. Liquidation preference of $0 at October 31, 2016 and 2015.Common Stock - $0.001 par value; 65,000,000 shares authorized, 40,057,067 shares issued and 40,041,047 shares outstanding at October 31, 2016 and 33,591,882 shares issued and 33,574,963 shares outstanding at October 31, 2015.Additional Paid-In Capital]Treasury Stock, at cost, 16,020 shares at October 31, 2016 and 16,919 shares October 31, 2015*TOTAL LIABILITIES AND SHAREHOLDERS EQUITY ADVAXIS, INC."STATEMENTS OF SHAREHOLDERS EQUITYPreferred Stock Common StockAdditional Paid-InTreasury Stock Accumulated Shareholders SharesAmountCapitalDeficitEquityBalance at October 31, 2013:Stock compensation to employees, directors and consultantsFTax withholdings paid related to net share settlement of equity awards-Common Stock issued upon exercise of warrants"Common Stock issued to consultants/Issuance of shares to employees under ESPP Plan?Issuance of shares to investors under stock purchase agreementsAdvaxis Public OfferingBalance at October 31, 2014FTreasury stock purchased to pay employee withholdings on equity awardsJTreasury shares sold to pay for employee tax withholdings on equity awards,Common Stock issued upon exercise of options-Conversion of notes payable into common stock#Advaxis registered direct offeringsBalance at October 31, 2015-Stock compensation to employees and directors-Common stock issued upon exercise of warrants"Common stock issued to consultantsSale of common shares to AmgenBalance at October 31, 2016Year ended October 31,OPERATING ACTIVITIESKAdjustments to reconcile Net Loss to net cash used in operating activities:Stock compensationNon-cash interest expenseBLoss (gain) on change in value of warrants and embedded derivativeWarrant expense*Gain on disposal of property and equipment&Loss on write-off of intangible assetsSettlement expenseEmployee stock purchase plan&Depreciation of property and equipment!Amortization of intangible assetsLease incentive obligation7Amortization of premium on held-to-maturity investmentsDebt conversion expenseGain on note retirement+Change in operating assets and liabilities:Interest receivablePrepaid expensesIncome taxes receivableOther current assetsDeferred expenses Other assets%Accounts payable and accrued expensesDeferred revenue Deferred rentInterest payable%Net cash used in operating activitiesINVESTING ACTIVITIES+Investments in held to maturity investmentsHProceeds from maturities and redemptions on held-to-maturity investments"Purchase of property and equipmentCost of intangible assets3Net cash provided by (used in) investing activitiesFINANCING ACTIVITIESRepayment of officer loan!Proceeds from exercise of options&Proceeds from the exercise of warrants(Net proceeds of issuance of common stock)Net cash provided by financing activities4Net increase (decrease) in cash and cash equivalents.Cash and cash equivalents at beginning of year(Cash and cash equivalents at end of year1Supplemental Disclosures of Cash Flow InformationCash paid for InterestCash < paid for TaxesCSupplemental Schedule of Noncash Investing and Financing Activities?Accounts payable and accrued Expenses settled with Common Stock-Conversion of notes payable into Common Stock*Sale of treasury shares pending settlementHProperty and equipment included in accounts payable and accrued expensesNet Loss per ShareAs of October 31,Warrants Stock Options0Convertible Debt (using the if-converted method)3. INVESTMENTSOctober 31, 2016Amortized cost, as adjusted Gross unrealized holding gains!Gross unrealized holding lossesEstimated fair valueShort-term investments:Certificates of Deposit"Domestic Governmental Agency LoansU.S Treasury Notes&Total short-term investment securitiesOctober 31, 20154. PROPERTY AND EQUIPMENTLeasehold ImprovementsLaboratory EquipmentFurniture and FixturesComputer EquipmentConstruction in ProgressTotal Property and Equipment)Accumulated Depreciation and AmortizationNet Property and Equipment5. INTANGIBLE ASSETSLicensePatentsSoftwareTotal intangiblesAccumulated AmortizationNet Intangible AssetsYear ending October 31,201720182019202020216. ACCRUED EXPENSES:Salaries and other compensationVendorsProfessional feesWithholding taxes payableTotal Accrued Expenses78. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY!Weighted Average Exercise Price8Weighted Average Remaining Contractual Life In YearsAggregate Intrinsic Value8Outstanding and Exercisable Warrants at October 31, 2013Issued ExercisedExpired8Outstanding and Exercisable Warrants at October 31, 2014 Exercised *8Outstanding and Exercisable Warrants at October 31, 20158Outstanding and Exercisable Warrants at October 31, 2016Warrant Liability 10/31/2016 10/31/2015 10/31/2014Exercise Price $10.63-18.75 $ 10.63-18.75 $ 2.76-21.25 Stock Price Expected Term0.55-0.75 years1.52-1.76 years0.01-2.76 years Volatility % 81.84%-87.09% 93.87%-95.00%55.41%-129.38%Risk Free Rate 0.51%-0.66%.075% .01-1.62%9. SHARE BASED COMPENSATION#For the Year Ended October 31, 2016Gross Purchase Net Purchase Executive $# of sharesDaniel J. O ConnorGregory T. MayesRobert G. PetitSara M. BonsteinRestricted Stock Units (RSUs) Number ofWeighted-AverageRSUsGrant Date Fair ValueBalance at October 31, 2013:GrantedVested CancelledBalance at October 31, 2014:Balance at October 31, 2015:Aggregate Intrinsic Value"Outstanding as of October 31, 2013Cancelled or Expired"Outstanding as of October 31, 2014"Outstanding as of October 31, 2015"Outstanding as of October 31, 2016*Vested and Exercisable at October 31, 2016Options OutstandingOptions ExercisableWeightedAverageExerciseNumber Remaining Intrinsic Price Range Outstanding ContractualPriceValue Exercisable $3.00 - $9.99$10.00 - $14.99$15.01 - $19.99$20.00 - $25.00 Year EndedOctober 31, 20145.51-6.51 years 5-10 years5 yearsExpected Volatility109.23%-115.25%109.26%-154.54%151.38-171.12%Expected Dividends0%Risk Free Interest Rate 1.65-2.00% 1.41%-2.27% 1.39%-1.72%Shares Issued to ConsultantsResearch and developmentGeneral and administrativeOffice & Laboratory Lease Thereafter12. INCOME TAXES:FederalCurrentDeferredState and LocalChange in valuation allowanceIncome tax provision (benefit) Years EndedDeferred Tax AssetsNet operating loss carryoversStock-based compensationOther deferred tax assetsTotal deferred tax assetsValuation allowance.Deferred tax asset, net of valuation allowanceDeferred Tax LiabilitiesOther deferred tax liabilitiesTotal deferred tax liabilities"Net deferred tax asset (liability)US Federal statutory rate34.0%(State income tax, net of federal benefitDeferred tax adjustment9Income tax benefit from sale of New Jersey NOL carryoversOther permanent differencesIncome tax (provision) benefit3.3%12.5%Beginning balance?Issuance of additional warrants due to anti-dilution provisionsChange in fair valueEnding Balance116. SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) Quarter EndedJanuary 31, 2016April 30, 2016 July 31, 2016Net loss3Net loss income per common share, basic and dilutedJanuary 31, 2015April 30, 2015 July 31, 2015January 31, 2014April 30, 2014 July 31, 2014 Advaxis INCTermSectionAdvaxisPreambleAdvaxis Indemnitee AgreementAlliance Manager2.1(b)AmgenAmgen IndemniteeAnnual Cap4.1(a)DCSI4.2(b)Dispute ClaimDSUREffective Date Infringement9.4(a)JSC2.1(a)Losses Milestone7.2(a)Milestone PaymentNon-Publishing PartyPharmacovigilance Agreement4.2(f) POC DatePOC NoticePublishing PartyQuality Agreement Quality Agreement Term Sheet#Regulatory Filing Transfer Date4.2(a)Regulatory Lead4.2(c)Sale Transaction14.5(a)Supply Agreement4.3(c)Supply Agreement Term SheetTechnology TransferThird Party Patent7.3(b)VAT8.3(c) EXHIBIT 23.1/s/ Marcum llpMarcum llpNew York, NYJanuary 9, 2017/(SECTION 302 OF THE SARBANES OXLEY ACT OF 2002)iI have reviewed this annual report on Form 10-K for the year ended October 31, 2016 of Advaxis, Inc.;6Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;#Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;PThe registrant s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)zDesigned such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)sDesigned such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrant s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluatio< n; and(d)Disclosed in this report any change in the registrant s internal control over financial reporting that occurred during the registrant s most recent fiscal quarter (the registrant s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant s internal control over financial reporting; and+The registrant s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant s auditors and the audit committee of the registrant s board of directors (or persons performing the equivalent functions):All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant s ability to record, process, summarize and report financial information; andAny fraud, whether or not material, that involves management or other employees who have a significant role in the registrant s internal control over financial reporting.By:/s/ Daniel J. O ConnorName:Daniel J. O ConnorTitle:)Chief Executive Officer and President/s/ Sara M. BonsteinSara M. Bonstein5Chief Financial Officer, Executive Vice PresidentDAS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002Date: January 9, 2017* 9G n<{? ™( cc   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  , ,,,,,       ~ ~ O  ~ ~   ~ ~  ~ ~ c Z PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }   ,,,,,      ~ ~ C ~ ,~  ~ $~   ~ ~ OR PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }   ,,,,,      Gz@~  ~ g~  ~ Gz@ ~ ~ R PH0 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} &} }  } }  } } [} } R} , @,,,,, , , , , ,,,,             ~ f~      ~ 5~      ~ n~      ~ = ףp @     ~ ~f~ k     ~ ~    ~ :~ #   ~  O~ G   ~ F~    ~ ;~    ~ f~      ~ &Qk"@     ~ KQk @    2 PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} G} }  } }  }  } } }  } }  } !,,,,,, , , , ,,,,,,,,,,,,  *   !   "   #  $  %       &~  '~   =  ' ' ( )~  ~ ^~ ~ #W~ : *~ 擏~ ~ 2~ )~ 5[ +~ ڊ0~  ~ J~ Ӏ~  ,~ H~ `e~ uW~ z,~ 6% - .~ &<~ ~  F7~ z~  /~ 6~ *~  F%~ ,~ J 0 1 1  1~ -~ wz 2~ ~ ~  z~ ~  3~ Ƹ~ 8g~  ~ ~ ( 4~ &Ú~ :b~  Bڏ~ C,~ * 5 1 1  1~ " ~  6~ {v~ r~  _ ~ 9~ ( 7~ {v~ r~  _~ <~ &S 8~    zG ~    ffffff ~  7  , 9~ Rp~ V~ F~ &1~ R     PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} <} }  } }  }  } } }  } }  }  ,,,,,,,, , :*   !   "   #  $  ; <~ B$~ Jx~  22 ~ e~  =~ ~ |~  V=~ 6~  >~ rM(~ &~  Vޒ~ ~  ?~ :~ q~  n~ :y'~ b @~ ޔz~ 6 ~  ~{B~ 3~  A~ ʠq~ n~ '~ zJ~ rZ   PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} /} ,, @,, , B C* D   E   F   G  H  I~ Y~ :~  . ~ N~ 2^ J~ TV~ TV K~ e~ bs@~  >%    PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,,, , , ,,,,,, L M~   Nffffff@ O~ [ P~  Q @ R ffffff@ Sq= ףp@ T~ s U~  Vffffff$@ W~  XPH 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,,, , , ,,,,,,,,, L M~ C Y~ k Z~  [~  \~  ]~   ^~  _~  `= ףp=$@ a(\B$@ b~  c~  d~  e~  fPH$0(  $>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ",,,, , , ,,,,,,,,,, L M g h~  i j k l m n o~  p q r s t u v w x~  y~  z { | } ~  !, ! !PH(0(  (>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} 6,,,, , , ,,,,,,,,,, L M        ~ ; ~ ? ~ C ~ G ~ K ~ O           !,#,%,',),+,-,/,1,3,5,~ !g !~ #k # % % ' ' ) ) + +~ - -~ / / 1 1~ 3 3~ 5 5PH,0(  ,>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} }  } }  } 0,,,,,,, , , , , ,,,,,,,,,,,,,,,  :   !   ~ ~ N ~ ` ~  ~ :~ N ~ z1~ f ~ ~ :b ~ ~ z- ~ .C~ 2 ~ &~ k ~ J ~ 2\B ~ :~ f ~ ~  ~ rM(~ &   ~ i~ |* ~ ~  ~ Ȕ 1 ~ t 1  1~  ?~ : 1 ~ V~  ,!,",#,$,&,(,),*,+,,,-,.,/, ~   1 !~ !" !1 "~ " "1 #? #1~ #q $~ $ ~ $ & ( ) )1 )1 *~ *q~ *  +~ +M~ +; ,~ ,~ ,> -@~ -ޔz~ -6 .A~ .ʠq~ .n /~ /rM(/~ /&/b ////PH00(  0>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} G} }  } }  }  } }  , , , , ,, , , , ,, , , , , , , , ,     !  "      &~  '~   =  ( )~  ~ ^~  *~ 擏~ ~ 2 +~ ڊ0~  ~ J ,~ H~ `e~ uW - .~ &<~ ~  F7 /~ 6~ *~  F% 2~ ~ ~  z 3~ Ƹ~ 8g~   4~ &Ú~ :b~  Bڏ 7~ {v~ r~  _  8~    zG ~   9~ Rp~ V~  F      PH40(  4>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} J} } }  } } }  } }  } }  } }  } }  } "} ## } $($,$ @$,$,$,$,$, $, $, $, $, $,$,$,$,$,$,$,$,$,$,$,$,$,$,$,$,$,$,$,         "#           "#  1 '~  dE~ b~  1 '~ 3~ "zJ# ~  N~ ~ S~ #b[ ~ p~ #p ~   1~ ~ # ~ ~ ~ J^~ #&^ ~  ~  ~ a~ #a ~ Ƅ~ N~  |~ #f'| ~ `~ RI~ R~ # 7~ _~ #_  1 '~   ~ 2~ Vy 1 '~ ~{B~ "'# ~  .0~ Z ~ bR~ #^ ~ V~ #V ~ ~ *G~ #*G ~ F~ ~ CI~  ~ #JMH ~  >~ ~ ~~ # ~  1*~  ~ ~ # ~  ~ ~ K~ #Q ~  "@~ ~ o~ #o ~  ^n~ ~ ~ # ~  V|~ ~  ~ # ~  ~ R2~ , ~ #2_ 7~ r~ #r  1 '~  *I~  ~ ;~ ~ >~ 6 ~ "n# ~  R5~  ~ 7~ #N7 ~ jA~ #jA ~ ~ kY~ #kY ~ ~ Y~ ~ ~ #& $,!$,"$,#$,$$,%$,&$,'$, ~ |~ ~ }%~ #% !~ ! N ~ !~ !^_~ !#_ "~ " &~ "~ "~ "# #~ # g~ #~ #Vx~ ##rx $~ $ n~ $#~ $d~ $#އ %~ % Z~ %/~ %V~ %# &7~ &{v~ &#{v ' '1 '''~ '  ~ 'q'~ 'M'~ '~ ''~ 'ޔz'~ '"ʠq'#B( "# "#"#"#"#''''''''''''"#PH80(  8>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} K} }  } }  }  } } 6 , , ,, ,, , , , , , , , , , , , , , ,, , , , , ,, , , ,     !  "   7~ {v~ r~  _   ~ ά~  ~  }G  1 1~  ~ ~ ~ 6  1~ ~ zE  1~ c 1  1~  1  1 1~  6 ~ rx~ ~  a ~ JN~ f~  n ~ k~ V ~   ~ *M 1  1 ~ l~   1  1~ g  1  1 1~  v  ~ ~ !  1 ~ ~ |~  V ~ ~~ q~  .T ~ ~  ~  1 ~ '~ Z ~  L ~ ~ B ~ >~ .B~   ~ ֤ 1  1 ~   1  1 ,! ,#,$ ,% ,& ,' ,( ,*,+ ,, ,- ,. ,/ ,0 ,1 ,2 ,3 ,4 ,5 ,  1 1~  ! ~ !`~ !">~ ! C* #  $ ~ $Flb~ $o $ 1 % ~ %B %1 % 1 & ~ &ZQ;~ &~ &  '~ '* ~ 'n~ ' b (~ (^~ (~ ( * * + +1 +1~ +  , ,1~ , , 1 -~ -%~ -~ -  .~ .~ ~ .~ . "y /~ /jA~ /V~ /  0~ 0kY~ 0*G 0 1 1~ 1&~ 1bG 1 1 2~ 2 ~ 2z1~ 2 < 3~ 3+ ~ 3 ~ 3 :=L 4~ 4N~ 422~ 4 e 5~ 55~ 5N5~ 5 225 Z    555555 PH<0(  <>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  , , , , ,     !  "   ' '~  VP  ~ B  '  ' Z     PH@0(  @>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} H}  , , , , , , ,     !  "  ~ b[ '~  I  ~ ~ o  '   '~ b  '   ~ & '  '       PHD0(  D>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 0} }  } }  }  } }  , , , , , , , ! "   !  "  #~ ڽ~ ~  2 $~ Γ~ x~   % 1~ ~  j4 ~ n~ V>~  *  PH H0(  H>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} &} }  } }  }  } } }  }  ,, @,,,, , & '  ( )  *  + , -~ n^ 1  1~ n^ .~  1~  ~  /~ 8~ %~  v~ &8 0~ `  ~ %~ y~ *` B  PH0L0(  L>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} &} }  } }  }  } } }  } , @,,,,, 1  ( )  *  + , -~ B 1  1~ B .~ F~ [~  n]~  /~ z2~  ~  ~ R2 0~  ~ e~  a~ v : PH@P0(  P>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} )} }  } }  }  ,,,,,,, , , , , 2 :   ! 3~ J p~ fz 4~ n|~ f| 5~ !~ ; 6~ :~  7~ "= ~ j 8~ %~ K 9~ f~ E :~ J  ~ 2\B B  PHPT0(  T>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,,,,,, , , ; :   ! <~ l/~ b' =~  /~  >~ 2 1 ?~ .`~ V @~ Z~  A~ : ~ f B  PH`X0(  X>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } ,,,,,, B  C~ b D~ b E~  F~  G~ 2PHp\0(  \>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,,,,,, , H :   ! I~ ~ g J~ ~ "2 K~ ~  L~ R~ | M~  ~  B  PH`0(  `>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 8} }  } }  }  } } , @,,,,, , , , , ,,,, N  O  P  Q R~ T~  ~  ~ [ S~ V0~  T~ :~  U~ E~ w V~ 2~ ~  +~  S~ $~ C W~  ~  U~ ~  X~ ~  ~ ~   S 1 T~ n~  U~ j~ O Y~ ڽ~ ~  ~ >bGj    PHd0(  d>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } } } }  } }  , , , , , , , Z [ \  ]  ^ _ `  a b~  ~ W~    c d e  f g h i  j k l m  nB  PHh0(  h>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,, ,,,, , o p  q  r  s t  t  u~ 2~ ~  j ~ zz v~ J~ 2~  ^M ~  ' w~ ~ 4~  J ~ b& x~ 2 ~ .~ 1 ~ #r      PHl0(  l>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  , , , , , , , , , , , , , , , , y z { | } ~~ ~  ~ mM~  ~ ~  ~ m(\@ ~ U0~   ~ 4~  ~ Vd~  ~ ~ c ~ ^DA~   ~ l*~  ~ ~  ~ ~  ~ b+~ J   PHp0(  p>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} *} }  } }  }  } } , @, ,,, , , , , , ,,, $  O  P   ~ N~ ~  c ' ~ 2Gz@~  S ~ 6~ g ~ ~ ?~   ' ~ e~ ~   W~ ~ 7 ~ ~ 8 ~ x~   q= ףp!@~ Jj  ~ T~  = ףp= @ ~ b~ g. ~ Γ~ ~  ; ~ r ~ U~ c~  # ~ rz   PHt0(  t>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  } }  } }  }  !!,!,!,!,!,!,!,!, !,                                                 ~ N~   Qk!@ ~ r~ N~  Qk!@~ r  ~ := ףp= @~    '~ @~  ~  '  ~ v ~  (\2@  '~ v ~ (\2@ '  ~  ~ ~ 7!  ' ~  ~ ~ 7!  ' 2                  PHx0(  x>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } } } }  } }   , , , , , ,  ' 1    c                   "  PH|0(  |>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  } }  , , , , , ,     !  "  ~ g~ ~$~  VL  ~ E~ ^~  & ~ ά~  ~  }G Z     PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  }  ,,,,,,, , , ,     C~ : D~ ? E~ C F~ .@K G~ "lP ~ 2^ ~ Y * PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  } }  , ,, , ,, , , , ,  ' 1      ' '  '  ~ r~ '~  W  ~ @<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} .} }  } }  } ,,,,,,,, , , , ,,  ' 1  ~ "S ~ ˆ1 ~ b~ Bs ~ 1Z~ º) ~ O~   ~ 9y~  ~ b ~ }   ~ 6~ D ~ 6 ~ D   ' 'j     PH00(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 9} }  } }  }  } }   , , , , , , , , ,  ' 1         ~ ; ~ ; ~  ; ~ !!~  !; ~ !+~ !~  !{ ~ +~ +~   ~ !ffffff~  !    "  PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ?} }  } }  } ,,,,,, :   ! ~ q~ n  1~  ~ ~  ~ :~ q*PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 3} }  } }  }  } } }  } ,,,,,,         ' &~ BB '  ' ~ b ~ D~ L~  "~ .] ~ !~ !O~  !C!R   PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 3} }  } }  }  } } }  } ,,,,,        1 & ' '  '  ' ~ ʯR~ W~  Z=~ . ~ !~ !3~  !S~ !kJ   PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 3} }  } }  }  } } }  } ,,,,,         & '~  =  '  ' ~ c~ r~  D~ 9 ~ !o~ ! !433333ӿ~ !J   PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} #} }  } $,,,,,,, , , , , ,,,,,,,,,,,,,,,,,,,      "~    "    "~ { "    "~     "      ~ {   "  "~  "  "~  "~  "~  "  "  "  "  "  "  "  ,!,",#, "   !~ ! ""  "  #  #  PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } ,,,,,  #    PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,@,@,@ ,@ , , ,,,,@,,, ~  ~  ~  ~            ~      !  "B  PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } )} ,@,,,,    # #$ % & ' (PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,@,@,@ ,@ , , ,,,,@,,, ~  ~  ~  ~            ~      !  "B  PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } 5} ,@,,,,   # #) % * ' +PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } )} ,,,, , - # #$ % & ' ( PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } 5} ,,,, , - # #) % * ' + PH0(  >@<dgg   FMicrosoft Excel 97-TabelleBiff8Oh+'0|8 @ L X d p0@@@Y@Y՜.+,D՜.+,\ H AppVersion DocSecurityHyperlinksChangedLinksUpToDate ScaleCrop ShareDoc12.0000 Root EntryFWorkbookvCompObjIOle SummaryInformation(DocumentSummaryInformation8h